WASHINGTON, United States – Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization. Third doses of the vaccine are recommended ...